Who is sponsoring NCT06664372?

NCT06664372 is sponsored by Assiut University.

What drugs are being tested in NCT06664372?

Interventions in NCT06664372: Trans fontanelle US Guided VP Shunt.

What condition does NCT06664372 study?

NCT06664372 studies Ventriculoperitoneal Shunt, Trans Fontanelle US, Congenital Hydrocephalus.

Is NCT06664372 still recruiting?

NCT06664372 is currently not yet recruiting. Last updated 29 October 2024.

Last reviewed 2024-10-29 · How we verify

NCT06664372

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Insertion of Frontal Ventricular Catheter of VP Shunt in Congenital Hydrocephalus Guided by Trans Fontanelle Ultrasound

Not yet recruiting NA Last updated 29 October 2024

What this trial tests

NA trial testing Trans fontanelle US Guided VP Shunt in Ventriculoperitoneal Shunt in 30 participants. Not yet recruiting.

Timeline

1 December 2024

Primary endpoint
1 December 2025

1 December 2026

Quick facts

Lead sponsor	Assiut University
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 December 2024
Primary completion	1 December 2025
Estimated completion	1 December 2026

Drugs / interventions tested

Trans fontanelle US Guided VP Shunt

Conditions studied

Ventriculoperitoneal Shunt — all drugs for Ventriculoperitoneal Shunt →
Trans Fontanelle US — all drugs for Trans Fontanelle US →
Congenital Hydrocephalus — all drugs for Congenital Hydrocephalus →

Sponsor

Assiut University

Who can join

Adults 5 Days to 2, any sex, with Ventriculoperitoneal Shunt or Trans Fontanelle US. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Aim of This Study Is To Evaluate The Role Of Ultrasound In Decreasing Rate Of Proximal Obstruction In Frontal VP Shunt

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06664372 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 29 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06664372.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing